0 9 Molecular molecular JJ 10 20 mechanisms mechanism NNS 21 23 of of IN 24 46 neutrophil-endothelial neutrophil-endothelial JJ 47 51 cell cell NN 52 60 adhesion adhesion NN 61 68 induced induce VBN 69 71 by by IN 72 77 redox redox NN 78 87 imbalance imbalance NN 87 88 . . . 90 98 Previous previous JJ 99 106 studies study NNS 107 111 have have VBP 112 122 implicated implicate VBN 123 124 a a DT 125 129 role role NN 130 133 for for IN 134 147 intracellular intracellular JJ 148 154 thiols thiol NNS 155 157 in in IN 158 161 the the DT 162 172 activation activation NN 173 175 of of IN 176 183 nuclear nuclear JJ 184 197 factor-kappaB factor-kappab NN 198 201 and and CC 202 217 transcriptional transcriptional JJ 218 228 regulation regulation NN 229 231 of of IN 232 243 endothelial endothelial JJ 244 248 cell cell NN 249 257 adhesion adhesion NN 258 267 molecules molecule NNS 267 268 . . . 269 273 This this DT 274 279 study study NN 280 283 was be VBD 284 292 designed design VBN 293 295 to to TO 296 305 determine determine VB 306 313 whether whether IN 314 321 changes change NNS 322 324 in in IN 325 336 endothelial endothelial JJ 337 341 cell cell NN 342 353 glutathione glutathione NN 354 355 ( ( ( 355 358 GSH GSH NNP 358 359 ) ) ) 360 362 or or CC 363 371 oxidized oxidize VBN 372 383 glutathione glutathione NN 384 385 ( ( ( 385 389 GSSG GSSG NNP 389 390 ) ) ) 391 394 can can MD 395 400 alter alter VB 401 411 neutrophil neutrophil NN 412 422 adhesivity adhesivity NN 423 426 and and CC 427 429 to to TO 430 436 define define VB 437 440 the the DT 441 450 molecular molecular JJ 451 460 mechanism mechanism NN 461 465 that that WDT 466 475 underlies underlie VBZ 476 480 this this DT 481 497 GSSG/GSH-induced gssg/gsh-induced JJ 498 506 adhesion adhesion NN 507 515 response response NN 515 516 . . . 517 526 Treatment Treatment NNP 527 529 of of IN 530 535 human human JJ 536 545 umbilical umbilical JJ 546 550 vein vein NN 551 562 endothelial endothelial JJ 563 567 cell cell NN 568 569 ( ( ( 569 574 HUVEC HUVEC NNP 574 575 ) ) ) 576 586 monolayers monolayer NNS 587 590 for for IN 591 592 6 6 CD 593 598 hours hour NNS 599 603 with with IN 604 607 0.2 0.2 CD 608 614 mmol/L mmol/l NN 615 622 diamide diamide NN 623 626 and and CC 627 628 1 1 CD 629 635 mmol/L mmol/l NN 636 646 buthionine buthionine NN 647 658 sulfoximine sulfoximine NN 659 660 ( ( ( 660 663 BSO BSO NNP 663 664 ) ) ) 665 674 decreased decrease VBD 675 678 GSH gsh NN 679 685 levels level NNS 686 689 and and CC 690 699 increased increase VBD 700 703 the the DT 704 709 ratio ratio NN 710 712 of of IN 713 717 GSSG gssg NN 718 720 to to TO 721 724 GSH gsh NN 725 732 without without IN 733 737 cell cell NN 738 746 toxicity toxicity NN 746 747 . . . 748 753 These these DT 754 759 redox redox NN 760 767 changes change NNS 768 771 are be VBP 772 779 similar similar JJ 780 782 to to TO 783 788 those those DT 789 797 observed observe VBN 798 802 with with IN 803 823 anoxia/reoxygenation anoxia/reoxygenation NN 823 824 . . . 825 832 Diamide Diamide NNP 833 837 plus plus CC 838 849 BSO-induced bso-induced JJ 850 865 thiol/disulfide thiol/disulfide NN 866 875 imbalance imbalance NN 876 879 was be VBD 880 890 associated associate VBN 891 895 with with IN 896 897 a a DT 898 906 biphasic biphasic JJ 907 915 increase increase NN 916 918 in in IN 919 929 neutrophil neutrophil NN 930 938 adhesion adhesion NN 939 941 to to TO 942 948 HUVECs huvec NNS 949 953 with with IN 954 958 peak peak NN 959 968 responses response NNS 969 977 observed observe VBN 978 980 at at IN 981 983 15 15 CD 984 991 minutes minute NNS 992 993 ( ( ( 993 998 phase phase NN 999 1000 1 1 CD 1000 1001 ) ) ) 1002 1005 and and CC 1006 1009 240 240 CD 1010 1017 minutes minute NNS 1018 1019 ( ( ( 1019 1024 phase phase NN 1025 1026 2 2 CD 1026 1027 ) ) ) 1027 1028 . . . 1029 1045 N-Acetylcysteine N-Acetylcysteine NNP 1046 1055 treatment treatment NN 1056 1066 attenuated attenuate VBD 1067 1077 neutrophil neutrophil NN 1078 1086 adhesion adhesion NN 1087 1089 in in IN 1090 1094 both both DT 1095 1101 phases phase NNS 1101 1102 , , , 1103 1108 which which WDT 1109 1118 indicated indicate VBD 1119 1120 a a DT 1121 1125 role role NN 1126 1129 for for IN 1130 1133 GSH GSH NNP 1134 1136 in in IN 1137 1140 the the DT 1141 1149 adhesion adhesion NN 1150 1159 responses response NNS 1159 1160 . . . 1161 1174 Interestingly interestingly RB 1174 1175 , , , 1176 1181 phase phase NN 1182 1183 1 1 CD 1184 1192 adhesion adhesion NN 1193 1196 was be VBD 1197 1206 inversely inversely RB 1207 1217 correlated correlate VBN 1218 1222 with with IN 1223 1226 GSH gsh NN 1227 1233 levels level NNS 1234 1237 but but CC 1238 1241 not not RB 1242 1246 with with IN 1247 1250 the the DT 1251 1259 GSSG/GSH gssg/gsh NN 1260 1265 ratio ratio NN 1265 1266 , , , 1267 1274 whereas whereas IN 1275 1280 phase phase NN 1281 1282 2 2 CD 1283 1293 neutrophil neutrophil NN 1294 1302 adhesion adhesion NN 1303 1306 was be VBD 1307 1317 positively positively RB 1318 1328 correlated correlate VBN 1329 1333 with with IN 1334 1342 GSSG/GSH gssg/gsh NN 1343 1348 ratio ratio NN 1349 1352 but but CC 1353 1356 not not RB 1357 1361 with with IN 1362 1365 GSH gsh NN 1366 1372 levels level NNS 1372 1373 . . . 1374 1387 Intercellular intercellular JJ 1388 1396 adhesion adhesion NN 1397 1407 molecule-1 molecule-1 NN 1408 1411 and and CC 1412 1431 P-selectin-specific p-selectin-specific JJ 1432 1442 monoclonal monoclonal JJ 1443 1453 antibodies antibody NNS 1454 1464 attenuated attenuate VBD 1465 1468 the the DT 1469 1478 increased increase VBN 1479 1489 neutrophil neutrophil NN 1490 1498 adhesion adhesion NN 1499 1505 during during IN 1506 1510 both both DT 1511 1517 phases phase NNS 1517 1518 , , , 1519 1526 whereas whereas IN 1527 1529 an an DT 1530 1545 anti-E-selectin anti-e-selectin JJ 1546 1556 monoclonal monoclonal JJ 1557 1565 antibody antibody NN 1566 1570 also also RB 1571 1581 attenuated attenuate VBD 1582 1585 the the DT 1586 1591 phase phase NN 1592 1593 2 2 CD 1594 1602 response response NN 1602 1603 . . . 1604 1616 Pretreatment Pretreatment NNP 1617 1621 with with IN 1622 1633 actinomycin actinomycin NN 1634 1635 D D NNP 1636 1639 and and CC 1640 1653 cycloheximide cycloheximide NN 1654 1656 or or CC 1657 1661 with with IN 1662 1671 competing compete VBG 1672 1691 ds-oligonucleotides ds-oligonucleotide NNS 1692 1696 that that WDT 1697 1706 contained contain VBD 1707 1714 nuclear nuclear JJ 1715 1728 factor-kappaB factor-kappab NN 1729 1731 or or CC 1732 1741 activator activator NN 1742 1751 protein-1 protein-1 NN 1752 1759 cognate cognate NN 1760 1763 DNA dna NN 1764 1773 sequences sequence NNS 1774 1787 significantly significantly RB 1788 1798 attenuated attenuate VBD 1799 1802 the the DT 1803 1808 phase phase NN 1809 1810 2 2 CD 1811 1819 response response NN 1819 1820 , , , 1821 1826 which which WDT 1827 1837 implicated implicate VBD 1838 1839 a a DT 1840 1844 role role NN 1845 1848 for for IN 1849 1851 de de FW 1852 1856 novo novo FW 1857 1864 protein protein NN 1865 1874 synthesis synthesis NN 1874 1875 . . . 1876 1883 Surface surface NN 1884 1894 expression expression NN 1895 1897 of of IN 1898 1911 intercellular intercellular JJ 1912 1920 adhesion adhesion NN 1921 1931 molecule-1 molecule-1 NN 1931 1932 , , , 1933 1943 P-selectin P-selectin NNP 1943 1944 , , , 1945 1948 and and CC 1949 1959 E-selectin E-selectin NNP 1960 1962 on on IN 1963 1969 HUVECs HUVEC NNP 1970 1980 correlated correlate VBD 1981 1985 with with IN 1986 1989 the the DT 1990 1995 phase phase NN 1996 1997 1 1 CD 1998 2001 and and CC 2002 2003 2 2 CD 2004 2014 neutrophil neutrophil NN 2015 2023 adhesion adhesion NN 2024 2033 responses response NNS 2033 2034 . . . 2035 2039 This this DT 2040 2045 study study NN 2046 2058 demonstrates demonstrate VBZ 2059 2063 that that IN 2064 2071 changes change NNS 2072 2074 in in IN 2075 2086 endothelial endothelial JJ 2087 2091 cell cell NN 2092 2100 GSSG/GSH gssg/gsh NN 2101 2106 cause cause VBP 2107 2132 transcription-independent transcription-independent JJ 2133 2136 and and CC 2137 2160 transcription-dependent transcription-dependent JJ 2161 2168 surface surface NN 2169 2179 expression expression NN 2180 2182 of of IN 2183 2192 different different JJ 2193 2204 endothelial endothelial JJ 2205 2209 cell cell NN 2210 2218 adhesion adhesion NN 2219 2228 molecules molecule NNS 2228 2229 , , , 2230 2235 which which WDT 2236 2241 leads lead VBZ 2242 2244 to to TO 2245 2246 a a DT 2247 2254 2-phase 2-phase NN 2255 2277 neutrophil-endothelial neutrophil-endothelial JJ 2278 2286 adhesion adhesion NN 2287 2295 response response NN 2295 2296 . . .